Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research note issued on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock. Titan Pharmaceuticals Price Performance NASDAQ TTNP opened at $5.73 on Friday. The business has a fifty day simple moving average […]

Leave a Reply

Your email address will not be published.

Previous post Verint Systems (NASDAQ:VRNT) Earns “Outperform” Rating from Royal Bank of Canada
Next post Badger Infrastructure Solutions Ltd. (TSE:BDGI) Receives C$50.00 Consensus Target Price from Analysts